Acute Kidney Injury due to Immunotherapy
Learn about Acute Kidney Injury due to Immunotherapy (AKI from Immune Checkpoint Inhibitors). This resource provides information on clinical documentation and medical coding for drug-induced acute kidney injury, supporting healthcare professionals in accurate diagnosis and reporting. Understand AKI due to immunotherapy and ensure proper documentation and coding practices.
Sudden kidney function decline caused by immunotherapy drugs.
Decreased urine output, swelling, fatigue, shortness of breath, elevated creatinine.
Oncology clinics treating patients with immune checkpoint inhibitors.
ICD-10 Code Families
Complete code families applicable to N14.1
When to use each related code
| Description | When to use |
|---|---|
| Acute kidney injury caused by immunotherapy drugs. | Use when AKI is temporally related to immunotherapy and other causes are excluded. Consider specific drug names. |
| Acute kidney injury from any drug, not just immunotherapy. | Use when AKI is temporally related to any medication and other causes are excluded. Specify the causative drug. |
| Chronic kidney disease resulting from long-term drug damage. | Use when chronic kidney impairment is attributed to cumulative drug toxicity, after excluding other etiologies. |
Best-practice checklist
- ✓Document immunotherapy agent, dose, and start date.
- ✓Specify AKI stage using KDIGO criteria.
- ✓Detail serum creatinine trends and urine output.
- ✓Rule out other causes of AKI (e.g., infection, dehydration).
- ✓Record relevant lab findings: BUN, electrolytes, urinalysis.
Common pitfalls to avoid
Coding AKI without specifying immunotherapy as the cause can lead to inaccurate data and reimbursement.
Failure to accurately code the specific immunotherapy agent can impact pharmacovigilance and research.
Overlooking comorbidities or complications associated with AKI and immunotherapy can affect quality reporting.
Best-practice tips
- 01Monitor renal function (creatinine, eGFR) before, during, and after immunotherapy. ICD-10 T88.7XXA, CDI: Timing specificity
- 02Promptly manage immune-related adverse events. ICD-10 T88.7XXA, CDI: Detailed documentation of symptoms
- 03Consider nephrology consult for AKI stages 2-3. Optimize hydration. ICD-10 N17.9, CDI: AKI Staging
- 04Discontinue or reduce immunotherapy dose as needed per guidelines and nephrology recommendations. ICD-10 T88.7XXA, CDI: Document rationale
- 05Document immunotherapy details, including drug name, dosage, and start/stop dates. ICD-10 T45.1X5A, CDI: Medication reconciliation
Step-by-step checklist
- 1
Verify immunotherapy initiation date and dosage.
- 2
Check creatinine/eGFR trends pre-, during, and post-therapy.
- 3
Assess urinalysis for signs of intrinsic AKI.
- 4
Review other nephrotoxic medication use.
- 5
Document AKI diagnosis with ICD-10 code (T78.4XXA).
Ready-to-paste narrative
Patient presents with acute kidney injury (AKI) likely secondary to immunotherapy treatment with immune checkpoint inhibitors. The patient's recent initiation of immunotherapy, specifically [Name of specific checkpoint inhibitor drug and dosage], is temporally related to the decline in renal function. Current serum creatinine is [Value] mg/dL, a significant increase from baseline of [Value] mg/dL. Estimated glomerular filtration rate (eGFR) has decreased to [Value] mL/min/1.73m2, indicating a stage [Stage of AKI based on KDIGO criteria] AKI. Urine output is [Volume] over the past 24 hours. Patient reports [Symptoms, e.g., fatigue, decreased urine output, edema]. Differential diagnosis includes prerenal azotemia, intrinsic acute tubular necrosis (ATN), and postrenal obstruction. However, the temporal association with immunotherapy, absence of evidence for volume depletion or obstruction, and [mention any other specific findings supporting immunotherapy-induced AKI, e.g., presence of inflammatory infiltrates on renal biopsy if performed] suggest drug-induced AKI as the most likely etiology. Immunotherapy-related adverse events are being closely monitored. Treatment plan includes holding the immunotherapy, careful fluid management, monitoring of electrolytes and renal function, and supportive care. Further investigation may include renal ultrasound and urinalysis to rule out other causes of AKI. ICD-10 code T78.4XXA, adverse effect of immunotherapy, and N17.9, acute kidney failure, unspecified, are considered. The patient will be closely monitored for improvement in renal function. Nephrology consultation may be considered if the patient's renal function does not improve.
Common questions and answers
How do I differentiate immune checkpoint inhibitor-induced acute kidney injury (ICI-AKI) from other causes of AKI in my oncology patients?+
Differentiating immune checkpoint inhibitor-induced acute kidney injury (ICI-AKI) from other causes requires a thorough clinical evaluation. Consider the patient's medication history, paying close attention to the timing of ICI initiation and AKI onset. ICI-AKI typically presents within weeks to months of starting therapy, although later onset can occur. Evaluate for other potential nephrotoxic agents the patient may be receiving, such as NSAIDs or certain antibiotics. Assess for signs of prerenal AKI (e.g., dehydration, hypotension) and postrenal obstruction. Urine microscopy can help distinguish acute interstitial nephritis (AIN), a common manifestation of ICI-AKI, from other causes. AIN often presents with sterile pyuria and white blood cell casts. Serum creatinine and urine output should be closely monitored. Kidney biopsy can provide definitive diagnosis in challenging cases. Explore how S10.AI can assist in the early identification and management of ICI-AKI in your oncology patients.
What are the best practices for managing acute kidney injury (AKI) caused by immune checkpoint inhibitors (ICIs) like pembrolizumab or nivolumab?+
Managing acute kidney injury (AKI) secondary to immune checkpoint inhibitors (ICIs) like pembrolizumab or nivolumab requires a multi-pronged approach. The first step is often to temporarily discontinue the ICI. The decision to re-challenge with the ICI after kidney function recovers should be made on a case-by-case basis, weighing the risks and benefits with the oncologist. Supportive care, including careful fluid management, is crucial. If the AKI is attributed to acute interstitial nephritis, corticosteroids are often employed. In more severe cases, dialysis may be necessary. Close monitoring of kidney function with serial serum creatinine and urine output measurements is essential. Consider implementing standardized protocols for early detection and management of ICI-AKI in your practice. Learn more about the latest research on ICI-AKI management and how S10.AI can support your clinical decision-making.
Several factors can increase the risk of developing acute kidney injury (AKI) from immunotherapy, including pre-existing chronic kidney disease, hypertension, diabetes, concurrent use of nephrotoxic medications, and older age. Mitigating these risks involves careful patient selection and monitoring. Baseline renal function assessment with serum creatinine and estimated glomerular filtration rate (eGFR) is crucial before initiating ICI therapy. Optimizing blood pressure and glycemic control in patients with hypertension and diabetes can help protect kidney function. Avoid or minimize the use of concomitant nephrotoxic medications whenever possible. Closely monitor renal function during ICI treatment, especially in high-risk patients. Consider implementing a risk stratification tool for AKI in your immunotherapy patients. Explore how S10.AI can help identify and manage these risk factors in your practice.+
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.